Lifecore Biomedical, Inc. LFCR
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | 05/25/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 5.31% | 5.31% | 0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 5.31% | 5.31% | 0.47% |
| Cost of Revenue | -- | -- | 10.29% | 10.29% | 2.50% |
| Gross Profit | -- | -- | -4.06% | -4.06% | -3.71% |
| SG&A Expenses | -- | -- | -7.55% | -7.55% | 12.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 3.64% | 3.64% | 4.80% |
| Operating Income | -- | -- | 32.49% | 32.49% | -134.47% |
| Income Before Tax | -- | -- | -654.87% | -654.87% | -506.50% |
| Income Tax Expenses | -- | -- | 472.86% | 472.86% | -76.50% |
| Earnings from Continuing Operations | -- | -- | -668.69% | -668.69% | -514.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -596.83% | -596.83% | -422.29% |
| EBIT | -- | -- | 32.49% | 32.49% | -134.47% |
| EBITDA | -- | -- | 118.52% | 118.52% | -154.59% |
| EPS Basic | -- | -- | -582.76% | -582.76% | -431.05% |
| Normalized Basic EPS | -- | -- | -293.15% | -293.15% | -303.05% |
| EPS Diluted | -- | -- | -2,219.60% | -2,219.60% | -676.98% |
| Normalized Diluted EPS | -- | -- | -433.62% | -433.62% | -414.33% |
| Average Basic Shares Outstanding | -- | -- | 19.16% | 19.16% | 14.23% |
| Average Diluted Shares Outstanding | -- | -- | 8.45% | 8.45% | 3.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |